【摘 要】
：
Purpose:To evaluate the efficacy of 5αRIs for BPH patients with large prostate (>80ml) at 3 years follow-up after TURP prospectively.Materials and methods:Eight-seven patients with large BPH were recr
【机 构】
：
Department of Urology, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine
【出 处】
：
第十次全国中西医结合男科学术大会暨第六届广西中医、中西医结合男科学术大会
论文部分内容阅读
Purpose:To evaluate the efficacy of 5αRIs for BPH patients with large prostate (>80ml) at 3 years follow-up after TURP prospectively.Materials and methods:Eight-seven patients with large BPH were recruited by three clinical centers from January 2007 to October 2014 in the study.Patients were randomized into a trial group (n=45) and a control group (n=42).The trial group took 5αRIs (either finasteride or dutasteride) after TURP, which lasted 3 years, while the control group took placebo.We evaluated the baseline characteristics and the indicators before, peri and after TURP(includingPV, PSA,Qm,PdetQm,IPSS,QoL, PVR,AUR, ,UTI,OM,RR,CDAO,H DAO,Re-TURP).Results: There were no significant differences in the baseline characteristics and the indicators between the trial group and control group before and peri TURP.In 6 months after TURP, there were significant differences in PSA and HU between the trial group and control group.But there were no significant differences in other indicators.And in the trial group, there were no significant differences in all indicators between the finasteride group and dutasteride group.In 3 years after TURP,there were significant differences in PV, PSA, Qm and HU between the trial group and control group.And in the trial group, there were significant differences in the PV, PSA,IPSS and QoL between the finasteride group and dutasteride group, but there were no significant differences in Qm,PdetQm,PVR,HU,UTI and Re-TURP between them.Conclusions: After TURP of large BPH, taking 5αRIs for 3 years can improve PV, PSA,Qm and HU, and dutasteride is better than finasteride in the improvement of PV, PSA,IPSS and QoL.
其他文献
目的 评价经肾上盏人路行经皮肾镜取石术(percutaneous nephrolithotomy,PCNL)的疗效及安全性.方法 回顾性分析2009年1月至2015年3月105例经肾上盏人路PCNL的临床资料,B超引导下选取肾上盏穿刺,采用穿刺架导航,准确穿刺肾上盏穹窿部,建立18F微创经皮肾通道,经皮肾输尿管镜下钬激光碎石.结果 105例均一期成功建立经皮肾通道并碎石.单通道为92例(87.6％
目的 比较分析钬激光碎石术与体外冲击波碎石术治疗输尿管结石的疗效.方法 将2011年3月至2014年1月我院应用钬激光碎石术治疗的50例输尿管结石患者,设立为观察组,另选择同期应用体外冲击波碎石术治疗的50例输尿管结石患者设立为对照组,比较两组患者碎石成功率、手术时间住院时间及并发症情况.结果 观察组50例患者的碎石成功率达94％,包括上段结石7例,中段结石15例,下段结石25例.观察组的碎石成功
Objective To evaluate the safety and feasibility of using the retroperitoneal laparoscopic partial nephrectomy (LPN) in the treatment of renal tumors measuring larger than 7 cm.Methods A total of 185
目的：观察萆薢分清丸联合盐酸坦索罗辛治疗ⅢA型前列腺炎的疗效,探讨中西药结合在治疗ⅢA型前列腺炎的作用与机制.方法：将156例40-50岁男性ⅢA型前列腺炎患者随机分为萆薢分清丸组和对照组.萆薢分清丸组78例给予萆薢分清丸联合盐酸坦索罗辛治疗,对照组78例给予盐酸坦索罗辛治疗,观察期1个月.萆薢分清丸组口服萆薜分清丸6.0g 3次/d,盐酸坦索罗辛2mg每晚1次,共30天.对照组口服盐酸坦索罗辛2
目的：证实是否通过氯喹的自噬抑制作用,促进骨化三醇对前列腺癌细胞凋亡的诱导.方法：用10或100 nM的骨化三醇,30 nM的氯喹,或两者联合使用,MTT法观察细胞增殖、PI染色流式细胞法检测细胞周期,台盘蓝染色细胞死亡数,anexin/PI染色法检测细胞凋亡,western法检测P62和LC3的表达观察细胞自噬.结果：与对照组相比100nM的骨化三醇干预48h,细胞抑制率达到25％,并将细胞周期
目的 探索保留尿道括约肌手术技巧在前列腺癌根治术中的应用效果.方法 本组80例前列腺癌患者,年龄66岁(范围59～75岁)；79例前列腺肿瘤限于T2b期以内,1例T3期；78例因PSA升高行术前经直肠超声波(TRUS)引导下的前列腺穿刺活检,Gleason分级3～7分,另2例为TURP后偶发癌；PSA平均8.5ng/ml(范围2.7～44.5 ng/ml).手术前均无尿失禁情况.手术技巧：处理阴茎
目的：前瞻性评估大体积前列腺增生(＞80克)TURP术后3年服用5α还原酶抑制剂的疗效.材料与方法：从2010年1月到2014年1月，有来自3个医疗中心的87例大体积前列腺增生患者最终完成本项研究.这些患者被随机分为试验组(n=45例)和对照组(n=42例)，试验组在TURP术后服用5α还原酶抑制剂3年(非那雄胺组n=28例，度他雄胺组n=17例)，对照组则服用安慰剂.我们评价基线、术前、术中、术
目的：探讨构建人类前列腺组织中富含亮氨酸重复和免疫球蛋白样结构域1 (LRIG1)基因重组腺病毒载体的技术方法.方法：以人前列腺组织总cDNA为模板,PCR反应扩增LRIG1基因；用纯化后的LRIG1扩增片段,在T4连接酶的作用下,混合T载体,连接产物转化DH5α超级感受态细胞,碱裂解法提取质粒(命名为T-LRIG1)并测序无误后将基因LRIG1连接穿梭质粒,在重组酶LR Clonase Ⅱ作用下
目的：观察腺病毒载体介导的抑癌基因LRIG1对前列腺癌细胞(PC-3细胞)增殖力、凋亡等生物学特性的影响,探讨LRIG1在前列腺癌发生发展中的机制.方法：从前列腺增生组织获取目的基因LRIG1并将其与腺病毒骨架质粒pAd/PL-DEST包装,获取正确的重组腺病毒质粒pAD-LRIG1并扩增后,提取得到高滴度pAD-LRIG1(1×108PFU/ml).将pAD-LRIG1按MOI=10加入PC-3
目的：探讨人前列腺LRIG1蛋白的三维结构同源模建，虚拟筛选LRIG1的功能蛋白。 方法：以LRIG1的同源蛋白LRRC4C蛋白的晶体结构(PDB号3ZYJ)为模型，通过MODELLER软件搭建LRIG1蛋白的三维空间结构；采用柔性对接的虚拟筛选技术，以荷兰SPECS公司的202490个化合物进行对接和打分，挑选出排名靠前的10个小分子化合物；通过AMBER软件分别进行20ns的分子动力学模拟，并